Ultrasound-guided hydrodissection has become an increasingly popular treatment for peripheral nerve entrapments over the past decade. While the technique is well established for conditions such as carpal tunnel syndrome, research specifically examining Baxter's nerve entrapment remains limited. This is largely because Baxter's nerve entrapment is frequently underdiagnosed and often grouped together with other causes of chronic heel pain rather than being studied as a separate condition.
The principle behind hydrodissection is straightforward. By using fluid to gently separate an irritated nerve from the surrounding fascia, muscle and connective tissue, the procedure aims to reduce mechanical compression and allow the nerve to move more freely. Ultrasound guidance allows the nerve, needle and injected fluid to be visualised throughout the procedure, improving precision and reducing the likelihood of injecting surrounding structures.
Most of the published evidence supporting hydrodissection comes from studies involving other peripheral nerves. Multiple systematic reviews have demonstrated improvements in pain, function and patient satisfaction for conditions such as carpal tunnel syndrome, where ultrasound-guided hydrodissection has become an increasingly accepted treatment option. These findings support the biological rationale behind the technique but cannot automatically be applied to Baxter's nerve entrapment because the anatomy and causes of compression differ.
One important limitation of the existing literature is that patient selection varies considerably. Some studies include patients with isolated Baxter's nerve entrapment, while others include individuals with coexisting plantar fasciosis, heel fat-pad disorders or other causes of chronic heel pain. This makes it difficult to determine how much of the improvement is attributable specifically to hydrodissection.
Another challenge is that there is currently no universally accepted hydrodissection protocol. Different clinicians use different fluid combinations, injection volumes and techniques. Some utilise normal saline, others dextrose, local anaesthetic or combinations of these solutions. Because these approaches differ between studies, direct comparison of outcomes remains difficult.
Despite these limitations, ultrasound guidance itself is strongly supported. Real-time visualisation allows accurate needle placement around the nerve, helps avoid blood vessels and other important structures and enables the clinician to observe the separation of tissue planes as the fluid is injected. Compared with blind injections based only on anatomical landmarks, ultrasound-guided procedures offer greater procedural precision.
The available evidence suggests that hydrodissection should not be viewed as a replacement for a comprehensive treatment programme. Patients continue to benefit from appropriate footwear, load management, strengthening, rehabilitation and treatment of any associated plantar fasciosis or biomechanical abnormalities. Hydrodissection is best considered as one component of a broader management strategy rather than a stand-alone solution.
The current evidence therefore supports cautious optimism. The biological rationale is sound, the technique is minimally invasive and early clinical reports are encouraging. However, the research remains in its early stages, and larger, well-designed clinical trials are still required before hydrodissection can be considered a standard treatment for Baxter's nerve entrapment.
For patients, the most important message is that hydrodissection should only be considered after an accurate diagnosis has confirmed that Baxter's nerve is likely to be contributing significantly to the heel pain. The success of any procedure depends far more on selecting the correct patient than simply performing the procedure itself.